Date event : March 30, 2018 - 2:00pm Conference / Talk Published on 03/26/2018 - 9:51am
Fibrotic liver disease is characterized by the deposition of excess connective tissue leading to diminished organ function and potentially liver failure. Commonly used models for in vitro liver fibrosis consist of culture-induced activation of rodent hepatic stellate cells (HSC), thereby ignoring the role of hepatocyte injury, which usually triggers the switch of quiescent HSCs into activated myofibroblastic HSCs in an injured liver. A brief review on the recent progress towards the development of 3D culture models of liver fibrosis will be provided. Thus far, only a few hepatic culture systems have successfully implemented HSCs (or other non-parenchymal cells) into hepatocyte cultures. We developed a human 3D hepatic organoid culture model, consisting of HepaRG cells and primary human HSCs. The hepatic organoids allow activation of HSCs in a drug- and hepatocyte-dependent manner when pro-fibrotic compounds are used. Further characterization of the organoids will be discussed as well as the use of mouse primary cells and hiPSC-derived cells. These 3D culture models represent an important step forward towards in vitro compound testing for drug-induced liver fibrosis
Friday March 30th, 2pm, SBRI conference room.
Invited by Pierre Yves Bourillot